Psilocybin Cuts Nerve Pain and Boosts Gabapentin in new Mouse Study
- Gauri Khanna
- 2 days ago
- 3 min read
A single dose of psilocybin reduced nerve pain in mice for several weeks and made the common painkiller gabapentin significantly more effective, according to new research from the University of Reading.
Rather than simply blocking pain signals, psilocybin appears to restructure the brain's pain-processing networks, which may explain why its effects persist long after the compound has cleared the body.
The findings matter because between 30 to 50 per cent of people with nerve pain do not get adequate relief from gabapentin alone, leaving a large patient population without good options.
Nerve pain, known clinically as neuropathic pain, arises when the nervous system itself is damaged or dysfunctional. Unlike the sharp sensation of a cut or bruise, it tends to be chronic, difficult to treat, and resistant to many standard painkillers. Gabapentin, one of the most widely prescribed drugs for the condition, fails to provide adequate relief for between 30 and 50 per cent of those who take it. The medicines that do work often carry serious risks, including dependency and significant side effects.
A Common Problem With Uncommon Solutions
That treatment gap is what makes a new study from the University of Reading, published in Communications Biology, particularly notable. Researchers tested psilocybin, the psychoactive compound found in magic mushrooms, in mice engineered to have nerve damage that produces long-lasting pain-like behaviour. Their findings suggest psilocybin may offer something that conventional painkillers do not: the ability to change how the brain processes pain at a network level, rather than simply dampening individual signals.
What the Study Found
The researchers gave mice a single injection of psilocybin and monitored pain responses over subsequent weeks. Pain relief became apparent around two hours after the dose and persisted for several weeks, well beyond the time the compound would remain active in the body.
The most striking result came from the interaction with gabapentin. When gabapentin was administered to mice weeks after their single psilocybin dose, at a point when psilocybin's own pain-relieving effect had already worn off, the painkiller produced relief lasting up to four days. In mice that had never received psilocybin, gabapentin's effect was considerably weaker. The implication, according to the authors, is that psilocybin may durably alter the brain's pain circuitry in a way that makes it more receptive to conventional treatment.
Dr Maria Maiarú, senior author from the University of Reading, described the potential as genuinely transformative for patients who have exhausted available options. The pain-relieving effect was confirmed in both male and female mice, which is methodologically significant; much early pain research was conducted in male animals only, leaving uncertainties about how findings translate across sexes.
Mechanism and Open Questions
The proposed mechanism centres on neuroplasticity: psilocybin's known capacity to promote the reorganisation of neural connections. Rather than acting as a conventional analgesic, it may reset the brain's pain-processing networks in a more lasting way. This aligns with broader research into psilocybin's effects on brain connectivity, including work relevant to its potential in mental health treatment.
However, the study's limitations are substantial and must be stated plainly. All experiments were conducted in mice, and the translation of animal pain models to human neuropathic pain is notoriously unreliable. The study used a small number of animals, in compliance with UK Home Office regulations and the 3Rs principles of Replacement, Reduction and Refinement. No human trials have been conducted to test these findings, and the dosing, timing, and interaction effects observed in mice may not hold in people.
